Safety Information Update for Healthcare Providers

There has been a change to the Prescribing Information. Click here to see changes.

>
ORILISSA® (elagolix) 150 mg and 200 mg Tablets

She's had enough of her moderate to severe endometriosis pain—she needs a change

Do you see patients like these in your practice?

Click on a profile to learn more about her story

Tap on a profile to learn more about her story

My pain comes and goes throughout the month, keeping me sidelined from things I care about like spending time with friends and family.

Reason for visit: Unresolved endometriosis pain

Diagnosed with endometriosis 4 years ago

Non-Menstrual Pelvic Pain Icon

Current Presentation:

  • Primary complaint: Non-menstrual pelvic pain
  • Patient has occasional dyspareunia
Prescription Icon

Current Treatment:

  • Progestin IUD
Clipboard Icon

Treatment History:

  • Rx NSAIDs, continuous OCs, progestins
Notepad Icon

Notes:

  • No plans to conceive within the next year
  • Would like the option to consider having another child in the future
  • All other conditions/causes for pain have been ruled out

Renee continues to suffer from her endometriosis pain. She may be ready for a treatment change.

ORILISSA may be an appropriate option for Renee

View ORILISSA safety profile

Due to my pain, I sometimes struggle to maintain focus at work. And I'm tired of compromising.

Reason for visit: Surgical consult for endometriosis

Diagnosed with endometriosis 8 years ago

Non-Menstrual Pelvic Pain Icon

Current Presentation:

  • Primary complaint: Non-menstrual pelvic pain
  • Patient has occasional dyspareunia
Prescription Icon

Current Treatment:

  • Progestin
Clipboard Icon

Treatment History:

  • OCs
  • Laparoscopy with post-operative treatment
Notepad Icon

Notes:

  • One child
  • Does not currently want a hysterectomy
  • All other conditions/causes for pain have been ruled out

Sabrina may be appropriate for surgery for her endometriosis pain. Where do alternative options fit within her journey?

ORILISSA may be an appropriate option for Sabrina

View ORILISSA efficacy

Sometimes I feel like I’m on the outside looking in. It’s hard to stay present when I’m in pain, and that can hold me back.

Reason for visit: Annual exam

Diagnosed with endometriosis 2 years ago

Non-Menstrual Pelvic Pain Icon

Current Presentation:

  • Primary complaint: Non-menstrual pelvic pain
  • Additional discomfort around time of menses
Prescription Icon

Current Treatment:

  • Continuous OCs
Clipboard Icon

Treatment History:

  • OTC NSAIDs
Notepad Icon

Notes:

  • No plans to conceive within the next year
  • Would like to keep options open to consider having children in the future
  • All other conditions/causes for pain have been ruled out

Fiona is early in her treatment journey, but she may be ready to try something other than OCs for her endometriosis pain.

ORILISSA may be an appropriate option for Fiona

View ORILISSA pharmacology
Renee, mid 30s
Sabrina, late 30s
Fiona, early 20s
Renee, a patient with unresolved pain
Renee, mid 30s
Tried multiple treatments and needs more relief
Sabrina, late 30s
Sabrina, late 30s
May be a candidate for surgery for her endometriosis pain, but is open to other options
Fiona, early 20s
Fiona, early 20s
Early in her treatment journey, but suffers from beyond mild endometriosis pain
Pharmacology

Indication and Important Safety Information

INDICATION1

ORILISSA® (elagolix) is indicated for the management of moderate to severe pain associated with endometriosis.

IMPORTANT SAFETY INFORMATION1

CONTRAINDICATIONS

  • ORILISSA is contraindicated in women who are pregnant (exposure to ORILISSA early in pregnancy may increase the risk of early pregnancy loss), in women with known osteoporosis or severe hepatic impairment, or with concomitant use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine and gemfibrozil).

WARNINGS AND PRECAUTIONS

Bone Loss

  • ORILISSA causes a dose-dependent decrease in bone mineral density (BMD), which is greater with increasing duration of use and may not be completely reversible after stopping treatment.
  • The impact of ORILISSA-associated decreases in BMD on long-term bone health and future fracture risk is unknown. Consider assessment of BMD in patients with a history of low-trauma fracture or other risk factors for osteoporosis or bone loss, and do not use in women with known osteoporosis.
  • Limit the duration of use to reduce the extent of bone loss.

Change in Menstrual Bleeding Pattern and Reduced Ability to Recognize Pregnancy

  • Women who take ORILISSA may experience a reduction in the amount, intensity, or duration of menstrual bleeding, which may reduce the ability to recognize the occurrence of pregnancy in a timely manner. Perform pregnancy testing if pregnancy is suspected, and discontinue ORILISSA if pregnancy is confirmed.

Suicidal Ideation, Suicidal Behavior, and Exacerbation of Mood Disorders

  • Suicidal ideation and behavior, including one completed suicide, occurred in subjects treated with ORILISSA in the endometriosis clinical trials.
  • ORILISSA users had a higher incidence of depression and mood changes compared to placebo and ORILISSA users with a history of suicidality or depression had an increased incidence of depression. Promptly evaluate patients with depressive symptoms to determine whether the risks of continued therapy outweigh the benefits. Patients with new or worsening depression, anxiety, or other mood changes should be referred to a mental health professional, as appropriate.
  • Advise patients to seek immediate medical attention for suicidal ideation and behavior. Reevaluate the benefits and risks of continuing ORILISSA if such events occur.

Hepatic Transaminase Elevations

  • In clinical trials, dose-dependent elevations of serum alanine aminotransferase (ALT) at least 3 times the upper limit of the reference range occurred with ORILISSA.
  • Use the lowest effective dose and instruct patients to promptly seek medical attention in case of symptoms or signs that may reflect liver injury, such as jaundice.
  • Promptly evaluate patients with elevations in liver tests to determine whether the benefits of continued therapy outweigh the risks.

Reduced Efficacy with Estrogen-Containing Contraceptives

  • Based on the mechanism of action of ORILISSA, estrogen-containing contraceptives are expected to reduce the efficacy of ORILISSA. The effect of progestin-only contraceptives on the efficacy of ORILISSA is unknown.
  • Advise women to use non-hormonal contraceptives during treatment and for one week after discontinuing ORILISSA.

ADVERSE REACTIONS

  • The most common adverse reactions (>5%) in clinical trials included hot flushes and night sweats, headache, nausea, insomnia, amenorrhea, anxiety, arthralgia, depression-related adverse reactions, and mood changes.

These are not all the possible side effects of ORILISSA.

Safety and effectiveness of ORILISSA in patients less than 18 years of age have not been established.

US-ORIL-200330

For more information, please click here for full Prescribing Information.

Reference:

1. ORILISSA [package insert]. North Chicago, IL: AbbVie Inc.

Indication and Important Safety Information

INDICATION1

ORILISSA® (elagolix) is indicated for the management of moderate to severe pain associated with endometriosis. Limit the duration of use based on the dose and coexisting condition.

IMPORTANT SAFETY INFORMATION1

CONTRAINDICATIONS

  • ORILISSA is contraindicated in women who are pregnant (exposure to ORILISSA early in pregnancy may increase the risk of early pregnancy loss), in women with known osteoporosis or severe hepatic impairment, in women taking organic anion transporting polypeptide (OATP) 1B1 inhibitors that are known or expected to significantly increase elagolix plasma concentrations, and in women with known hypersensitivity reaction to ORILISSA or any of its inactive components. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Bone Loss

  • ORILISSA causes a dose-dependent decrease in bone mineral density (BMD), which is greater with increasing duration of use and may not be completely reversible after stopping treatment.
  • The impact of ORILISSA-associated decreases in BMD on long-term bone health and future fracture risk is unknown. ORILISSA is contraindicated in women with known osteoporosis. Consider assessment of BMD in patients with a history of low-trauma fracture or other risk factors for osteoporosis or bone loss.
  • Limit the duration of use to reduce the extent of bone loss.

Change in Menstrual Bleeding Pattern and Reduced Ability to Recognize Pregnancy

  • Women who take ORILISSA may experience a reduction in the amount, intensity, or duration of menstrual bleeding, which may reduce the ability to recognize the occurrence of pregnancy in a timely manner. Perform pregnancy testing if pregnancy is suspected, and discontinue ORILISSA if pregnancy is confirmed.

Suicidal Ideation, Suicidal Behavior, and Exacerbation of Mood Disorders

  • Suicidal ideation and behavior, including one completed suicide, occurred in subjects treated with ORILISSA in the endometriosis clinical trials.
  • ORILISSA users had a higher incidence of depression and mood changes compared to placebo and ORILISSA users with a history of suicidality or depression had an increased incidence of depression. Promptly evaluate patients with depressive symptoms to determine whether the risks of continued therapy outweigh the benefits. Patients with new or worsening depression, anxiety, or other mood changes should be referred to a mental health professional, as appropriate.
  • Advise patients to seek immediate medical attention for suicidal ideation and behavior. Reevaluate the benefits and risks of continuing ORILISSA if such events occur.

Hepatic Transaminase Elevations

  • In clinical trials, dose-dependent elevations of serum alanine aminotransferase (ALT) at least 3 times the upper limit of the reference range occurred with ORILISSA.
  • Use the lowest effective dose and instruct patients to promptly seek medical attention in case of symptoms or signs that may reflect liver injury, such as jaundice.
  • Promptly evaluate patients with elevations in liver tests to determine whether the benefits of continued therapy outweigh the risks.

Interactions with Hormonal Contraceptives

  • Advise women to use effective non-hormonal contraceptives during treatment and for 28 days after discontinuing ORILISSA.
  • Coadministration of ORILISSA 200 mg twice daily with an estrogen-containing contraceptive is not recommended because of the potential for increased estrogen-associated risks including thromboembolic disorders and vascular events. Coadministration of ORILISSA with an estrogen-containing contraceptive is expected to reduce the efficacy of ORILISSA.
  • Coadministration with progestin-containing oral contraceptives may reduce the efficacy of the contraceptive. The effect of progestin-only contraceptives on the efficacy of ORILISSA is unknown. Coadministration of ORILISSA with progestin-containing intrauterine contraceptive systems has not been studied.

ADVERSE REACTIONS

  • The most common adverse reactions (>5%) in clinical trials included hot flushes and night sweats, headache, nausea, insomnia, amenorrhea, anxiety, arthralgia, depression-related adverse reactions, and mood changes.

These are not all the possible side effects of ORILISSA.

Safety and effectiveness of ORILISSA in pediatric patients have not been established.

US-ORIL-210045

For more information, please click here for full Prescribing Information.

Reference:

1. ORILISSA [package insert]. North Chicago, IL: AbbVie Inc.

Legal Notices/Privacy Policy. Copyright 2021, AbbVie Inc., North Chicago, Illinois, U.S.A. If you have any questions about AbbVie’s ORILISSA.com website that have not been answered, click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patients must be made with a healthcare provider and consider the unique characteristics of each patient.

©2021 AbbVie Inc. North Chicago, IL 60064

US-ORIL-210099

You are leaving an AbbVie website and connecting to a site that is not under the control of AbbVie.

AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's endorsement of ORILISSA.com/HCP or AbbVie.

Do you wish to leave this site?

Cancel
Continue

Dysmenorrhea results in ELARIS EM-2

Co-primary endpoint: Responder rate for dysmenorrhea at month 31*

ELARIS EM-2

ORILISSA 150 mg QD
43%
(n=221)
Placebo
23%
(n=353)

P≤0.001 vs placebo

Secondary endpoint: Mean dysmenorrhea pain reduction from baseline on the Endometriosis Daily Pain Impact Scale1,3,6†‡§

ELARIS EM-2

Mean dysmenorrhea score at month 6:
ORILISSA 150 mg QD (n=185): 1.06
Placebo (n=273): 1.64

*Dysmenorrhea responder threshold was ≥0.81-point decrease from baseline in ELARIS EM-1 and ≥0.85-point decrease from baseline in ELARIS EM-2. NMPP responder threshold was ≥0.36-point decrease from baseline in ELARIS EM-1 and ≥0.43-point decrease from baseline in ELARIS EM-2.

†In ELARIS EM-1 and EM-2, the mean changes in dysmenorrhea and NMPP scores from baseline to month 6 were secondary endpoints.

‡In ELARIS EM-1 and EM-2, the mean changes in dysmenorrhea and NMPP scores from baseline to each month (except month 6) were non-ranked secondary endpoints. Appropriate multiplicity adjustments were not applied.

§Baseline and monthly visit values were based on a 35-day mean.

Dysmenorrhea results in ELARIS EM-2

Co-primary endpoint: Responder rate for dysmenorrhea at month 31*

ELARIS EM-2

ORILISSA 200 mg BID
72%
(n=225)
Placebo
23%
(n=353)

P≤0.001 vs placebo

Secondary endpoint: Mean dysmenorrhea pain reduction from baseline on the Endometriosis Daily Pain Impact Scale1,3,6†‡§

ELARIS EM-2

Mean dysmenorrhea score at month 6:
ORILISSA 200 mg BID (n=187): 0.43
Placebo (n=273): 1.64

*Dysmenorrhea responder threshold was ≥0.81-point decrease from baseline in ELARIS EM-1 and ≥0.85-point decrease from baseline in ELARIS EM-2. NMPP responder threshold was ≥0.36-point decrease from baseline in ELARIS EM-1 and ≥0.43-point decrease from baseline in ELARIS EM-2.

†In ELARIS EM-1 and EM-2, the mean changes in dysmenorrhea and NMPP scores from baseline to month 6 were secondary endpoints.

‡In ELARIS EM-1 and EM-2, the mean changes in dysmenorrhea and NMPP scores from baseline to each month (except month 6) were non-ranked secondary endpoints. Appropriate multiplicity adjustments were not applied.

§Baseline and monthly visit values were based on a 35-day mean.

Dyspareunia results in ELARIS EM-2

Secondary endpoint: Mean dyspareunia pain reduction from baseline on the Endometriosis Daily Pain Impact Scale3*†

ELARIS EM-2

ORILISSA 150 mg QD
Mean change in dyspareunia score at month 3 was not statistically significant3

*Baseline and monthly visit values were based on a 35-day mean.

†In ELARIS EM-1 and EM-2, the mean changes from baseline in dyspareunia scores were evaluated as secondary endpoints vs placebo at month 3 and as non-ranked secondary endpoints at each month (except month 3). Appropriate multiplicity adjustments were not applied to the non-ranked secondary endpoints.

Dyspareunia results in ELARIS EM-2

Secondary endpoint: Mean dyspareunia pain reduction from baseline on the Endometriosis Daily Pain Impact Scale1,3,6*†

ELARIS EM-2

Mean dyspareunia score at month 6:
ORILISSA 200 mg BID (n=137): 0.71
Placebo (n=189): 1.11

*Baseline and monthly visit values were based on a 35-day mean.

†In ELARIS EM-1 and EM-2, the mean changes from baseline in dyspareunia scores were evaluated as secondary endpoints vs placebo at month 3 and as non-ranked secondary endpoints at each month (except month 3). Appropriate multiplicity adjustments were not applied to the non-ranked secondary endpoints.

Non-menstrual pelvic pain (NMPP) results in ELARIS EM-2

Co-primary endpoint: Responder rate for NMPP at month 31*

ELARIS EM-2

ORILISSA 150 mg QD
50%
(n=221)
Placebo
37%
(n=353)

P≤0.001 vs placebo

Secondary endpoint: Mean NMPP pain reduction from baseline on the Endometriosis Daily Pain Impact Scale1,3,6†‡§

ELARIS EM-2

Mean NMPP score at month 6:
ORILISSA 150 mg QD (n=185): 1.00
Placebo (n=273): 1.07

*Dysmenorrhea responder threshold was ≥0.81-point decrease from baseline in ELARIS EM-1 and ≥0.85-point decrease from baseline in ELARIS EM-2. NMPP responder threshold was ≥0.36-point decrease from baseline in ELARIS EM-1 and ≥0.43-point decrease from baseline in ELARIS EM-2.

†In ELARIS EM-1 and EM-2, the mean changes in dysmenorrhea and NMPP scores from baseline to month 6 were secondary endpoints.

‡In ELARIS EM-1 and EM-2, the mean changes in dysmenorrhea and NMPP scores from baseline to each month (except month 6) were non-ranked secondary endpoints. Appropriate multiplicity adjustments were not applied.

§Baseline and monthly visit values were based on a 35-day mean.

Non-menstrual pelvic pain (NMPP) results in ELARIS EM-2

Co-primary endpoint: Responder rate for NMPP at month 31*

ELARIS EM-2

ORILISSA 200 mg BID
58%
(n=225)
Placebo
37%
(n=353)

P≤0.001 vs placebo

Secondary endpoint: Mean NMPP pain reduction from baseline on the Endometriosis Daily Pain Impact Scale1,3,6†‡§

ELARIS EM-2

Mean NMPP score at month 6:
ORILISSA 200 mg BID (n=187): 0.73
Placebo (n=273): 1.07

*Dysmenorrhea responder threshold was ≥0.81-point decrease from baseline in ELARIS EM-1 and ≥0.85-point decrease from baseline in ELARIS EM-2. NMPP responder threshold was ≥0.36-point decrease from baseline in ELARIS EM-1 and ≥0.43-point decrease from baseline in ELARIS EM-2.

†In ELARIS EM-1 and EM-2, the mean changes in dysmenorrhea and NMPP scores from baseline to month 6 were secondary endpoints.

‡In ELARIS EM-1 and EM-2, the mean changes in dysmenorrhea and NMPP scores from baseline to each month (except month 6) were non-ranked secondary endpoints. Appropriate multiplicity adjustments were not applied.

§Baseline and monthly visit values were based on a 35-day mean.

IMPORTANT SAFETY INFORMATION1

CONTRAINDICATIONS

ORILISSA is contraindicated in women who are pregnant (exposure to ORILISSA early in pregnancy may increase the risk of early pregnancy loss), in women with known...

INDICATION1

ORILISSA® (elagolix) is indicated for the management of moderate to severe pain associated with endometriosis. Limit the duration of use based on the dose and coexisting condition.

IMPORTANT SAFETY INFORMATION1

CONTRAINDICATIONS

ORILISSA is contraindicated in women who are pregnant (exposure to ORILISSA early in pregnancy may increase the risk of early pregnancy loss), in women with known osteoporosis or severe hepatic impairment...

INDICATION1

ORILISSA® (elagolix) is indicated for the management of moderate to severe pain associated with endometriosis. Limit the duration of use based on the dose and coexisting condition.

IMPORTANT SAFETY INFORMATION1

CONTRAINDICATIONS

ORILISSA is contraindicated in women who are pregnant (exposure to ORILISSA early in pregnancy may increase the risk of early pregnancy loss), in women with known...

INDICATION1

ORILISSA® (elagolix) is indicated for the management of moderate to severe pain associated with endometriosis. Limit the duration of use based on the dose and coexisting condition.

IMPORTANT SAFETY INFORMATION1

CONTRAINDICATIONS

ORILISSA is contraindicated in women who are pregnant (exposure to ORILISSA early in pregnancy may increase the risk of early pregnancy loss), in women with known osteoporosis or severe hepatic impairment...

INDICATION1

ORILISSA® (elagolix) is indicated for the management of moderate to severe pain associated with endometriosis. Limit the duration of use based on the dose and coexisting condition.

Indication and Important Safety Information

INDICATION1

ORILISSA® (elagolix) is indicated for the management of moderate to severe pain associated with endometriosis. Limit the duration of use based on the dose and coexisting condition.

IMPORTANT SAFETY INFORMATION1

CONTRAINDICATIONS

  • ORILISSA is contraindicated in women who are pregnant (exposure to ORILISSA early in pregnancy may increase the risk of early pregnancy loss), in women with known osteoporosis or severe hepatic impairment, in women taking organic anion transporting polypeptide (OATP) 1B1 inhibitors that are known or expected to significantly increase elagolix plasma concentrations, and in women with known hypersensitivity reaction to ORILISSA or any of its inactive components. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Bone Loss

  • ORILISSA causes a dose-dependent decrease in bone mineral density (BMD), which is greater with increasing duration of use and may not be completely reversible after stopping treatment.
  • The impact of ORILISSA-associated decreases in BMD on long-term bone health and future fracture risk is unknown. ORILISSA is contraindicated in women with known osteoporosis. Consider assessment of BMD in patients with a history of low-trauma fracture or other risk factors for osteoporosis or bone loss.
  • Limit the duration of use to reduce the extent of bone loss.

Change in Menstrual Bleeding Pattern and Reduced Ability to Recognize Pregnancy

  • Women who take ORILISSA may experience a reduction in the amount, intensity, or duration of menstrual bleeding, which may reduce the ability to recognize the occurrence of pregnancy in a timely manner. Perform pregnancy testing if pregnancy is suspected, and discontinue ORILISSA if pregnancy is confirmed.

Suicidal Ideation, Suicidal Behavior, and Exacerbation of Mood Disorders

  • Suicidal ideation and behavior, including one completed suicide, occurred in subjects treated with ORILISSA in the endometriosis clinical trials.
  • ORILISSA users had a higher incidence of depression and mood changes compared to placebo and ORILISSA users with a history of suicidality or depression had an increased incidence of depression. Promptly evaluate patients with depressive symptoms to determine whether the risks of continued therapy outweigh the benefits. Patients with new or worsening depression, anxiety, or other mood changes should be referred to a mental health professional, as appropriate.
  • Advise patients to seek immediate medical attention for suicidal ideation and behavior. Reevaluate the benefits and risks of continuing ORILISSA if such events occur.

Hepatic Transaminase Elevations

  • In clinical trials, dose-dependent elevations of serum alanine aminotransferase (ALT) at least 3 times the upper limit of the reference range occurred with ORILISSA.
  • Use the lowest effective dose and instruct patients to promptly seek medical attention in case of symptoms or signs that may reflect liver injury, such as jaundice.
  • Promptly evaluate patients with elevations in liver tests to determine whether the benefits of continued therapy outweigh the risks.

Interactions with Hormonal Contraceptives

  • Advise women to use effective non-hormonal contraceptives during treatment and for 28 days after discontinuing ORILISSA.
  • Coadministration of ORILISSA 200 mg twice daily with an estrogen-containing contraceptive is not recommended because of the potential for increased estrogen-associated risks including thromboembolic disorders and vascular events. Coadministration of ORILISSA with an estrogen-containing contraceptive is expected to reduce the efficacy of ORILISSA.
  • Coadministration with progestin-containing oral contraceptives may reduce the efficacy of the contraceptive. The effect of progestin-only contraceptives on the efficacy of ORILISSA is unknown. Coadministration of ORILISSA with progestin-containing intrauterine contraceptive systems has not been studied.

ADVERSE REACTIONS

  • The most common adverse reactions (>5%) in clinical trials included hot flushes and night sweats, headache, nausea, insomnia, amenorrhea, anxiety, arthralgia, depression-related adverse reactions, and mood changes.

These are not all the possible side effects of ORILISSA.

Safety and effectiveness of ORILISSA in pediatric patients have not been established.

US-ORIL-210045